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1.  INTRODUCTION 
Levofloxacin is a broad spectrum anti-infective agent, 
which is rapidly and completely absorbed after oral 
administration. The half life of Levofloxacin is 6-8 h 
after conventional dosing 
1
. Recently the research interest 
is evolving to develop a drug delivery system with the 
use of biodegradable polymers. Nanoparticles have huge 
awareness as potential drug delivery devices in the 
appliance of controlled and targeted release for various 
absorptive tissues by improving the intracellular 
penetration. Moreover it represents an attractive 
alternative for improving the modulation of drug 
delivery, shelf life and stability in biological fluids 
2
. 
Oral drug delivery is the most attractive and favoured 
manner of drug delivery for achieving mutually systemic 
and local therapeutic effects. But a variety of problems 
are also related with the conventional oral dosage forms, 
that it is frequently essential to take several times per day 
to retain the concentration of administered drug within 
the therapeutically effective range which results in a 
fluctuated drug level and consequently undesirable 
toxicity and poor efficiency. So to overcome such 
problems associated with conventional oral dosage form, 
the idea of controlled drug delivery systems was 
introduced 
3
.  
The real challenge in the development of a controlled 
drug delivery system is not just to control the drug 
release, also to extend the existence of the dosage form 
in the absorption site until all the drug is completely 
released in the preferred period of time 
4-6
.  
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ABSTRACT 
Background: Levofloxacin is a broad spectrum anti-infective agent, which is rapidly and completely absorbed after oral 
administration. The half life of Levofloxacin is 6-8 h after conventional dosing. The objective of the present work was to 
develop Levofloxacin nanoparticles to retain the dosage form in the absorption site more than the half life of the drug, enhance 
the bioavailability of drugs, reduce dose frequency, toxicity and patient compliance.  
Methods: The compositions of different formulations of Levofloxacin nanoparticles by the ionic gelation method using 
biodegradable polymer chitosan and tripolyphosphate as cross linking agent.  
Result and Discussion: The particle size lies of the prepared nanoparticles between 199 and 369 nm and the drug content 
found between 51.13± 0.28 and 71.12 ± 0.14 %. The particle size of nanoparticles increased with increasing concentration of 
polymer matrix density and this may be due to the increased viscosity of the inner phase and decreased with increasing 
concentration of β-cyclodextrin. Scanning electron microscopy indicated that the prepared nanoparticles were discrete, uniform 
and spherical with a smooth surface. The in vitro release showed that the drug release from the prepared nanoparticles was 
characterized by an initial fast release and followed by a delayed release phase. During and at the end of the accelerated 
stability study, the tested formulation showed almost same drug content, in vitro drug release and no colour changes were 
observed from that observed at the opening of the study. 
Conclusion: Among all the formulations (GIA, GIB, GIC, GID, GIE and GIF), the formulations G1C, G1E and G1F followed 
the drug release in a controlled manner. The in vitro release profile showed that this is a potential drug delivery for 
Levofloxacin and has to confirm in the in vivo settings as a separate investigation in future.  
Key words: Controlled drug delivery, In vitro drug release, Nanoparticle, Particle size, Stability studies, Surface morphology 
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Continuous release of the drug involves polymers that 
release the drug at a controlled manner due to the 
degradation of polymer over time and it can be achieved 
by using drug carrying polymer. 
In the present work, our aim was to develop a new 
nanoparticulate drug carrier that combines the benefits 
of chitosan nanoparticles and cyclodextrins to enhance 
the bioavailability of drugs, retain the drug in the 
absorption site more than the half life of the drug, 
reduce dose frequency, toxicity and patient compliance. 
2. MATERIALS AND METHODS 
2.1 Materials 
Levofloxacin was a gifted sample from Orchid 
Chemicals, Chennai, India. Chitosan (low molecular 
weight) and Sodium TriPolyphosphate were purchased 
from Central Fisheries Department, Cochin, India. 
Sodium hydroxide and acetic acid was supplied from 
Merck (India) Ltd, Mumbai. The β-cyclodextrin was 
provided from Yarrow Chemicals, Mumbai, India. All 
other reagents used were of analytical grade. 
2.2 Methods 
2.2.1 Solubility studies 
Higuchi and Connors method were used to determine 
the phase solubility 
7
. Levofloxacin which exceeded its 
solubility in phosphate buffer solution (pH 6.8), was 
transferred to a screw capped vials containing 25 mL of 
aqueous solution of β-cyclodextrin at various 
concentrations (0, 5, 7.5, 10, 13 and 15  mM) 
[8]
. The 
above mixture was stirred for 48 h, at 37 ± 0.1 
o
C and 
2000 rpm on a rotary shaker to obtain equilibrium of 
mixture. After reaching equilibrium, samples were 
filtered through membrane filter (100 μm) and after 
suitable dilution, assayed spectrophotometrically 
(Shimadzu 1800, Japan) at 287 nm. 
2.2.2 Formulation of Levofloxacin -chitosan/ β-
cyclodextrin nanoparticles 
Complexation of Levofloxacin with β-cyclodextrin was 
developed using liquid / liquid co-precipitation method 
8, 9
. The composition of different formulations of 
Levofloxacin nanoparticles by the ionic gelation 
method is shown in Table 1. Chitosan gel solution 
(0.2% w/v) was prepared using glacial acetic acid and 
stabilized overnight to obtain clear solution 
[10]
. 
Tripolyphosphate solution (0.1, 0.3, 0.5 % w/v) were 
prepared in distilled water and added drop wise with a 
syringe to the above gel solution with constant stirring. 
The prepared Levofloxacin - β-cyclodextrin complex 
(different ratios) was added to the above chitosan gel 
solution and the resulting suspension was subsequently 
centrifuged at 10000 rpm for 10 min, further the pellets 
obtained were resuspended in deionised water by 
sonication, then centrifuged and dried at room 
temperature 
11, 12
. 
 
Table 1: Compositions of LEV- chitosan / β-cyclodextrin nanoparticles 
 
 
 
 
 
 
 
2.3 Evaluations 
2.3.1 Physicochemical and Morphological 
characterization of Nanoparticles 
Particle size determinations (Malvern Particle Size 
Analyzer, Mastersizer 2000, USA), of samples were 
prepared by dispersing nanoparticles with sufficient 
amount of water to achieve obscuration around 5%. 
From the particle size distribution data, the average 
particle size was determined 
12
. 
2.3.2 Encapsulation efficiency of Levofloxacin 
For this, nanoparticles were dissolved in ethanol and 
ultracentrifuged at 10000 rpm for 30 min. The 
supernatant solution was separated and assayed at 287 
nm. The encapsulation efficiency of Levofloxacin was 
calculated as follows 
13, 14
. 
Entrapment efficiency (%) = (Tp – Tf) 100/Tp 
            Where,  
            Tp = Total LEV used 
            Tf = Free LEV in the supernatant 
2.3.3 Drug content 
100 mg of Levofloxacin loaded nanoparticles were 
dissolved in phosphate buffer (pH 6.8) and stirred in 
sonicator for 4 h at 30 
o
C. The samples were filtered 
using 0.2 µm filter and assayed at 287 nm.  
2.3.4 In vitro release study 
At first 900 mL of 0.1N HCl (pH 1.2) was used as the 
dissolution medium for 2 h and then same volume of 
phosphate buffer (pH 6.8) was replaced in the 
dissolution apparatus for 10 h at 50 rpm and 
temperature was maintained at 37 ±1
 o
C. USP XXIII, 
type-II dissolution test apparatus was used to carry out 
in vitro drug release studies (Electrolab, EDT-08Lx) 
[15]
. 
Weighed samples, were placed in a dialysis membrane 
and immersed into the dissolution medium. One mL of 
Formulations Levofloxacin: Chitosan: β-cyclodextrin Tripoly Phosphate (%) 
G1A 1:1:1 0.1 
G1B 1:2:1.5 0.1 
G1C 1:3:2 0.3 
G1D 1:1:2.5 0.3 
G1E 1:2:3 0.5 
G1F 1:3:3.5 0.5 
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sample was withdrawn every one hour for 12 h interval 
and replaced with equal quantity of the dissolution 
medium. After appropriate dilution the samples were 
assayed at 287 nm. The mechanism of drug release 
from the nanoparticles was determined by finding 
Higuchi and Korsmeyer-Peppas plots 
[16-19]
.  
2.3.5 Surface morphology  
Shape and surface morphology of Levofloxacin 
nanoparticles were studied using scanning electron 
microscopy). For shape and surface morphology the 
nanoparticles were mounted on metal stubs and the stub 
was then coated with conductive gold with sputter 
coater attached to the instrument Jeol scanning electron 
microscope (SEM, JEOL-JSM-AS430, Japan) and the 
photographs were taken. 
2.3.6 Zeta potential determination 
The zeta potential was determined by diluting the 
samples with 0.1 mM KCl solution and it is adjusted to 
pH 7.4 
[20]
. The surface charge of Levofloxacin 
nanoparticles was determined using Zetasizer Nano ZS 
(Malvern Instruments, Malvern, UK).  
2.3.7 Accelerated stability studies 
The selected formulations was subjected to stability by 
wrapping them in an aluminum foil and packed in an 
amber colored bottle. These nanoparticles were kept in 
an incubator maintained at 40 ± 0.2 °C and 75 ± 5 % 
RH for 6 months. Changes in the appearance, drug 
content and in vitro dissolution studies of the stored 
nanoparticles were investigated. 
3. RESULTS AND DISCUSION 
3.1 Formulation of LEV – chitosan / β-cyclodextrin 
nanoparticles 
LEV nanoparticles were prepared by ionic gelation 
method using chitosan / β-cyclodextrin. 
Tripolyphosphate solution were added as the cross 
linking in the formulation step. All the prepared 
formulations (six) were evaluated for particle size, drug 
content, drug entrapment efficiency and in vitro drug 
release. Depends upon the release profile the selected 
formulations were used for further evaluations such as 
surface morphology, zeta potential and stability studies. 
3.2 Particle size, drug content and drug entrapment 
efficiency 
The particle size and drug content of the prepared LEV 
nanoparticles are shown in Table 2. The particle size 
lies between 199 and 369 nm and the drug content 
found between 51.13± 0.28 and 71.12 ± 0.14 %. The 
particle size of nanoparticles increased with increasing 
concentration of polymer matrix density and this may 
be due to the increased viscosity of the inner phase and 
decreased with increasing concentration of β-
cyclodextrin. The drug entrapment efficiency differed 
between 59.07 ± 1.2 and 74.45 ± 1.92 % (Fig. 1), 
indicated that, this is increased with increasing 
concentration of chitosan and β-cyclodextrin. All the 
formulations showed very well drug content also.
  
 
Table 2: Particle size and drug content of LEV- β-cyclodextrin 
 
 
 
 
 
 
*Mean, SD ± n=3       
  
 
Figure 1: Drug entrapment efficiency of the formulations 
Formulation code Particle size (nm)* Drug content (%)* 
G1A 369 51.13± 0.28 
G1B 310 59.22 ± 0.32 
G1C 207 70.89± 0.32 
G1D 285 59.12 ± 0.22 
G1E 260 60.01 ± 0.16 
G1F 199 71.12 ± 0.14 
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3.3 Invitro release study 
The in vitro release of LEV from different nanoparticles 
is shown in Fig. 2. The maximum in vitro release was 
evaluated to be 91.5 ± 2 % over a period of 12 h for the 
formulation G1A. All other formulations G1B, GIC, 
G1D, G1E and G1F showed highest release of ˃ 80 % 
at the end of 12 h. The complexation with the 
cyclodextrin permits a protection for sensitive drug and 
in vitro release profile observed for these nanoparticles 
was characterized by an erratic drug release in the 
beginning and followed by a delayed release phase. A 
strong reduction of cyclodextrin solubilizing efficiency 
towards the drug was observed, when chitosan and 
cyclodextrin present at the same time. Controlled drug 
delivery systems, release the drug through a variety of 
complex mechanisms, and are not yet entirely clear. 
This may be governed by either purely diffusion or 
purely erosion controlled. The results indicated that the 
release of the drug decreased with increasing 
concentration of chitosan and also, β-cyclodextrin 
provides an additional element for controlling the 
release of LEV from the formulations. Among all the 
formulations, G1C, G1E and G1F followed the drug 
release in a controlled manner and further used for 
surface morphology, zeta potential and stability studies.  
The release data of the tested nanoparticles were 
analyzed on the basis of Korsmeyer-Peppas equation 
and Higuchi kinetics 
[16-19]
. The R
2
, k and n values are 
given in Table 3. The formulations G1E and G1F were 
best fitted to super case II transport drug release, 
according to this drug release mechanism could be due 
to increased plasticization at the relaxing boundary. But 
the formulation G1C provided good fit to the Higuchi 
model. The drug release from these nanoparticles may 
be controlled by diffusion through the micropores. 
 
  
 
Figure 2: The in vitro drug release of the formulations 
Table 3: The R
2
, k and n values of selected formulations 
 
3.4 Surface morphology and Zeta potential 
determination 
Scanning electron microscopy indicated that the 
prepared nanoparticles were discrete, uniform and 
spherical with a smooth surface. The monographs of 
selected formulations are shown in Fig. 3. The Zeta 
potential of selected formulations is shown in Table 4. 
The surface charge of LEV - β-cyclodextrin 
nanoparticles was stronger and the LEV molecules were 
released slowly [the amount released slowly (˂ 80 %) 
within 12 h] due to the electrostatic attraction between 
the drug and nanoparticles. This indicated that, the 
formation of nanoparticle depended dramatically on the 
concentration of free amino groups, which increase the 
zeta potential of the nanoparticles. 
  Table 4: The Zeta potential of selected formulations 
*Mean, SD ± n=3
 
Formulations 
Higuchi Korsmeyer-Peppas Mechanism of drug 
release R
2
 k (h
-1
) R
2
 n 
G1C 0.9345 ˃1 0.9205 ˃1 Higuchi kinetics 
G1E 0.8949 ˃1 0.9050 ˃1 Super case II transport 
G1F 0.870 ˃1 0.8884 ˃1 Super case II transport 
Formulations Zeta potential 
(mV)* 
G1C 31.8 ± 0.28 
G1E 31.3 ± 0.17 
G1F 28.7 ± 0.45 
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Figure 3: The surface morphology of the selected formulations
3.5 Accelerated stability studies 
During and at the end of the stability study, the tested 
formulation showed almost same drug content, in vitro 
drug release and no color changes from that observed at 
the opening of the study. 
4. CONCLUSIONS 
Levofloxacin nanoparticles can be formulated using 
chitosan and β-cyclodextrin by ionic gelation method. 
The in vitro release profile showed that maximum 
amount of Levofloxacin is released from the prepared 
nanoparticles in a controlled manner. From this, it 
concluded that this is a potential drug delivery for 
Levofloxacin and pertaining to these studies, this has to 
confirm in the in vivo settings as a separate 
investigation in future.  
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